Literature DB >> 27168662

High Hepatitis C Infection Rate Among Baby Boomers in an Urban Primary Care Clinic: Results from the HepTLC Initiative.

Alexander G Geboy1, Sandeep Mahajan2, Allison P Daly1, Candice F Sewell3, Ike C Fleming1, Hyun A Cha1, Idene E Perez1, Carmella A Cole3, Adebisi A Ayodele3, Dawn A Fishbein4.   

Abstract

OBJECTIVE: CDC recommends that all people born between 1945 and 1965 be tested for hepatitis C virus (HCV). We hypothesized that HCV testing in a large, urban primary care clinic would reveal higher rates of HCV infection than previously published.
METHODS: Through the Hepatitis Testing and Linkage to Care initiative, the primary care clinic at MedStar Washington Hospital Center in Washington, DC, provided HCV antibody (anti-HCV) testing and linkage to care from October 2012 through September 2013 for patients born between 1945 and 1965 without previously noted risk factors. We collected data on age, race/ethnicity, sex, anti-HCV and HCV ribonucleic acid (RNA) results, risk factors in those who tested anti-HCV positive, and health insurance type and made comparisons using c(2) and Student's t-tests.
RESULTS: Of 1,123 patients tested, the mean age was 57 years, 742 (66.1%) were women, 969 (86.3%) were black/African American, and 654 (58.2%) had public health insurance. Of the 99 (8.8%) patients who tested anti-HCV positive, the mean age was 58 years, 54 were men, and 93 were black/African American; 41 of 74 anti-HCV-positive patients were intravenous drug users. Of 82 anti-HCV-positive patients, 51 were HCV RNA positive. Of the black/African American patients tested, 49 of 317 men (15.5%) and 44 of 652 women (6.7%) were anti-HCV positive (p,0.001). The HCV prevalence rate in the birth cohort (8.8%) was significantly higher than the U.S. (3.3%) and DC (2.5%) rates (p,0.001), and the HCV prevalence rate among black/African American men in DC (15.5%) was substantially higher than the prevalence rate reported by CDC (8.1%).
CONCLUSION: Testing initiatives in primary care settings need to be more rigorously upheld, and internal champions are needed to advocate for increased screening to ensure linkage to care and engagement in the HCV care cascade.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27168662      PMCID: PMC4853329          DOI: 10.1177/00333549161310S209

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  13 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

3.  Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

7.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

Review 8.  The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States.

Authors:  John W Ward
Journal:  Clin Liver Dis       Date:  2013-02       Impact factor: 6.126

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Public health impact of antiviral therapy for hepatitis C in the United States.

Authors:  Michael L Volk; Rachel Tocco; Sameer Saini; Anna S F Lok
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.298

View more
  14 in total

1.  Race and Hepatitis C Care Continuum in an Underserved Birth Cohort.

Authors:  Nicole J Kim; Cameron J Locke; Helen Park; Catherine Magee; Peter Bacchetti; Mandana Khalili
Journal:  J Gen Intern Med       Date:  2018-09-20       Impact factor: 5.128

2.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

3.  Universal HCV Screening of Baby Boomers is Feasible, but It is Difficult.

Authors:  Paul J Thuluvath; Joshua Trowell; Talan Zhang; Joseph Alukal; George Lowe
Journal:  J Clin Exp Hepatol       Date:  2021-02-25

4.  Hepatitis C Virus Screening: Factors Associated With Test Completion in a Large Academic Health Care System.

Authors:  Monica L Kasting; Shannon M Christy; Richard R Reich; Julie A Rathwell; Richard G Roetzheim; Susan T Vadaparampil; Anna R Giuliano
Journal:  Public Health Rep       Date:  2021-10-25       Impact factor: 3.117

5.  Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era.

Authors:  Sarah C Dupont; Shelly-Ann Fluker; Kristi M Quairoli; Cameron Body; Ike Okosun; Jennifer Lom; Lesley S Miller
Journal:  Public Health Rep       Date:  2019-11-22       Impact factor: 2.792

6.  Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era.

Authors:  O Falade-Nwulia; A McAdams-Mahmoud; R Irvin; A Niculescu; K R Page; M Mix; D L Thomas; M S Sulkowski; S H Mehta
Journal:  J Community Med Health Educ       Date:  2016-10-28

7.  Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.

Authors:  Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Nipaporn Siripon; Nawarat Posuwan; Chompoonut Auphimai; Sirapa Klinfueng; Napha Thanetkongtong; Viboonsak Vuthitanachot; Supapith Saiyatha; Chaiwat Thongmai; Saowakon Sochoo; Panthip Sukthong; Kittiyod Poovorawan; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

8.  Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination.

Authors:  Rujipat Wasitthankasem; Napaporn Pimsingh; Khuandao Treesun; Nawarat Posuwan; Preeyaporn Vichaiwattana; Chompoonut Auphimai; Ilada Thongpan; Sissades Tongsima; Sompong Vongpunsawad; Yong Poovorawan
Journal:  Am J Trop Med Hyg       Date:  2020-05-07       Impact factor: 2.345

9.  Liver cancer incidence and mortality: Disparities based on age, ethnicity, health and nutrition, molecular factors, and geography.

Authors:  Santosh Kumar Singh; Rajesh Singh
Journal:  Cancer Health Disparities       Date:  2020-03

10.  Routine Screening and Linkage to Care for Hepatitis C Virus in an Urban Safety-Net Health System, 2017-2019.

Authors:  Bijou R Hunt; Christopher Ahmed; Kimberly Ramirez-Mercado; Christopher Patron; Nancy R Glick
Journal:  Public Health Rep       Date:  2020-11-11       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.